Modulight Spotlights Theralase's Anti-viral ResearchDr. McFarland uses Finland based Modulight lasers in her lab.
Modulight's ML6600 laser was also used in the University of Manitoba Ruvidar anti-viral research.
Modulight Spotlights: LASER-SHARP RESEARCH – June 2024 A promising new therapy against viruses was developed at University of Manitoba and Theralase Technologies. Infectious agents are a global problem, causing millions of deaths every year. The study evaluated antiviral effectiveness of a cancer drug (Ruvidar), which is currently in clinical development for bladder cancer. When this drug was activated with green laser using Modulight’s ML6600, it resulted in a rapid elimination of many different human viruses. Impressively, it was >99% effective at low doses in inactivating human coronavirus, influenza virus, vaccinia virus, Zika virus, and herpes simplex virus. These results are an important step forward in addressing the issues with antibiotic resistance and emerging new pathogens, for which it typically takes years to develop vaccines and other selective therapies.
Modulight is very happy to be supporting this research. We would like to deliver our warmest congratulations to the research team!
About Modulight’s LASER-SHARP RESEARCH concept:
Laser-Sharp Research is a concept where our scientific board highlights cutting-edge scientific research articles from our customers. Important selection criteria are that Modulight and laser product are mentioned in the publication, the impact and relevance of the results, clinical translatability, as well as scientific quality of the journal. The nominated research groups will be rewarded to encourage the great work done.